Differences of IPSS, Q Max and Prostate Volume Before and After Treatment with Combination of Dutasteride and Tamoxifen in BPH Patient without Urine Retention Seputra Kurnia P.1, Soebadi Doddy M.1, Widayat Hedromartono1, Widoda J.P.1, Soetojo1,* 1Department of Urology, Faculty of Medicine, Airlangga University, Surabaya, 60115, Indonesia *Corresponding author: Soetojo, E-mail: soetojo@fk.unair.ac.id
Online published on 30 April, 2019. Abstract Benign Prostate Hyperplasia (BPH) is the common benign enlargement that found in men who suffers from urinary difficulties and the incidence increases as they are getting older. This study compare the IPSS, Q max and volume of the prostate between pre and post treatment of 5 α Deductase inhibitor and Tamoxifen in patients BPH without urine retention. About 40 patients who had been diagnosed BPH without urine retention is participating in this study. The study has classified them in to 4 groups, each group contain of 10 patients and were given Tamoxifen, Dutasteride, Combination (Tamoxifen with Dutasteride) and Placebo. The collected data includes the IPSS, uroflowmetry and volume of the prostate before and after 3 months of treatment. The data is analyzed by SPSS 12. The obtained results show Q max and IPSS have significantly improved in Dutasteride and combination group. While, Tamoxifen treatment group shows no significant improvements in Q max and IPSS. All the treatment groups show significant decreasing of prostate volume except Placebo group. Top Keywords Benign Prostate Hyperplasia (BPH), Dutasteride, Lower Urinary Tract Symptom (LUTS), Placebo, Tamoxifen. Top |